A 28 Week Extension to a 24 Week Multi-center, Randomized, Double-blind Clinical Trial to Evaluate the Safety and Tolerability of Vildagliptin (50 mg qd) Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency
Latest Information Update: 24 Aug 2016
At a glance
- Drugs Vildagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Novartis
- 17 Feb 2013 New trial record
- 04 May 2012 Trial status changed from active, no longer recruiting to completed as reported by ClinicalTrails.gov record (Extension trial: NCT00765830).